Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.

The lower payments female oncologists received may reflect a “disadvantage in terms of career trajectories for women,” according to researchers.

Under former President Joe Biden, enrollment in Medicaid hit a record high, and the uninsured rate reached a record low. President Donald Trump’s return to the White House — along with a ...

The FDA has approved Datroway (datopotamab deruxtecan) to treat adults with unresectable or metastatic, HR+, HER2- breast cancer who have received prior endocrine therapy and chemotherapy.

A growing body of research suggests that exposure to PFAS, commonly called "forever chemicals," may increase a person's risk ...

The decline in cancer incidence among men and increase among women has narrowed the male‐to-female cancer incidence rate ratio from a peak of 1.6 in 1992 to 1.1 in 2021. In people aged 50-64 years, ...

The FDA has said it cannot approve tabelecleucel to treat patients 2 years of age and older who have EBV-positive PTLD and have received at least 1 prior therapy.

More than 2 million new cases of cancer will be diagnosed in the US this year, and more than 600,000 people will die of cancer, researchers project.

Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

The FDA has approved Calquence (acalabrutinib) for use in combination with bendamustine and rituximab to treat adults with previously untreated MCL who are ineligible for transplant.

Per- and polyfluoroalkyl substances (PFAS) in drinking water is associated with cancer incidence, a new study suggests.